SCHEMBL3465686

SCHEMBL3465686

COc1cccc(OC)c1-c1ccc(S(=O)(=O)O)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.45
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
EGFR P00533 1/20 0.39
PIM1 P11309 1/20 0.39
NAPRT Q6XQN6 1/20 0.39
IDO1 P14902 2/20 0.37
LMNA P02545 1/20 0.37
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
CA7 P43166 2/20 0.36
CA9 Q16790 2/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HTR7 P34969 1/20 0.36
CA12 O43570 1/20 0.36
CA14 Q9ULX7 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1206409 0.84 CA2 (0.53) CA1CA2EGFRLMNAHSP90AA1
SCHEMBL1207418 0.82 FLT1 (0.45) KDM4EMEN1KMT2A
SCHEMBL1206402 0.81 FLT1 (0.46) KDM4ECA1CA2MEN1KMT2A
SCHEMBL1206941 0.80 CSF1R (0.43) CA1CA2MEN1KMT2ACA9
SCHEMBL8438731 0.79 KDM4E (0.65) KDM4ENAPRTLMNAHTTSMN1; SMN2
SCHEMBL1205856 0.78 MAPK10 (0.41)
SCHEMBL9239536 0.77 KDM4E (0.63) KDM4ENAPRTLMNAHTTSMN1; SMN2
SCHEMBL31188687 0.77 CA1 (0.48) CA1CA2MEN1KMT2AEGFR
SCHEMBL5204232 0.75 HTR7 (0.42) KDM4EMEN1KMT2AHTTSMN1; SMN2
SCHEMBL1207558 0.74 LMNA (0.40) MEN1KMT2ALMNAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256200-A1 ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-07 US disclosed
CN-101675033-A Aryl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents HOFFMANN LA ROCHE 2010-03-17 CN disclosed
EP-2148861-A1 ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. Hoffmann-Roche AG (CH) 2010-02-03 EP disclosed
WO-2008138594-A1 ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256200-A1 ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS ARSA, STS, SULT2A1 KDM4E 2156/4885CA1 4728/4885CA2 3219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.